Zacks Research Issues Positive Outlook for JAZZ Earnings

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) – Investment analysts at Zacks Research lifted their Q3 2026 EPS estimates for Jazz Pharmaceuticals in a research note issued to investors on Friday, October 23rd. Zacks Research analyst Team now expects that the specialty pharmaceutical company will post earnings of ($5.14) per share for the quarter, up from their previous estimate of ($5.24). The consensus estimate for Jazz Pharmaceuticals’ current full-year earnings is $18.24 per share. Zacks Research also issued estimates for Jazz Pharmaceuticals’ Q4 2026 earnings at $5.28 EPS, FY2026 earnings at $10.28 EPS and Q4 2027 earnings at $5.11 EPS.

JAZZ has been the topic of a number of other research reports. Morgan Stanley cut their price target on Jazz Pharmaceuticals from $322.00 to $314.00 and set an “overweight” rating on the stock in a report on Wednesday, October 21st. Needham & Company LLC increased their price objective on Jazz Pharmaceuticals from $292.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, August 26th. The Goldman Sachs Group began coverage on Jazz Pharmaceuticals in a research report on Thursday, September 24th. They issued a “buy” rating and a $337.00 target price on the stock. Piper Sandler lifted their target price on Jazz Pharmaceuticals from $301.00 to $310.00 and gave the company an “overweight” rating in a research note on Tuesday, August 4th. Finally, Weiss Ratings upgraded Jazz Pharmaceuticals from a “hold (c-)” rating to a “buy (b-)” rating in a research report on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $290.85.

Jazz Pharmaceuticals Price Performance

NASDAQ JAZZ opened at $205.70 on Tuesday. The company has a 50-day moving average price of $235.29 and a two-hundred day moving average price of $215.34. Jazz Pharmaceuticals has a 52 week low of $128.80 and a 52 week high of $266.38. The stock has a market cap of $13.35 billion, a price-to-earnings ratio of 9.26, a price-to-earnings-growth ratio of 0.26 and a beta of 0.37. The company has a current ratio of 1.78, a quick ratio of 1.58 and a debt-to-equity ratio of 0.69.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share for the quarter, missing analysts’ consensus estimates of $6.18 by ($0.47). The firm had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.11 billion. Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%. The firm’s revenue was up 15.5% on a year-over-year basis. During the same period last year, the business earned ($8.25) EPS.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Hedge funds have recently modified their holdings of the company. USA Financial Formulas bought a new stake in shares of Jazz Pharmaceuticals in the 1st quarter worth $25,000. Pension & Wealth Management Advisors Inc. bought a new position in Jazz Pharmaceuticals during the third quarter valued at about $32,000. Ameritas Advisory Services LLC bought a new position in Jazz Pharmaceuticals during the second quarter valued at about $47,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in Jazz Pharmaceuticals during the second quarter valued at about $61,000. Finally, Elevation Wealth Partners LLC boosted its stake in Jazz Pharmaceuticals by 156.4% during the third quarter. Elevation Wealth Partners LLC now owns 259 shares of the specialty pharmaceutical company’s stock valued at $60,000 after buying an additional 158 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Jazz Pharmaceuticals

In other news, EVP Neena Patil sold 1,200 shares of the stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $240.94, for a total value of $289,128.00. Following the completion of the transaction, the executive vice president directly owned 47,671 shares in the company, valued at $11,485,850.74. This trade represents a 2.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Robert Iannone sold 76,921 shares of the firm’s stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $249.70, for a total transaction of $19,207,173.70. Following the transaction, the executive vice president owned 65,686 shares in the company, valued at $16,401,794.20. This represents a 53.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 100,121 shares of company stock valued at $24,855,802. 4.10% of the stock is currently owned by insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.